Connect Biopharma Holdings Limited to Post FY2023 Earnings of ($2.11) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CNTB)

Connect Biopharma Holdings Limited (NASDAQ:CNTBGet Rating) – Investment analysts at Cantor Fitzgerald issued their FY2023 earnings estimates for shares of Connect Biopharma in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn ($2.11) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

Several other research firms have also weighed in on CNTB. SVB Leerink initiated coverage on Connect Biopharma in a research report on Friday, April 1st. They set a “buy” rating and a $22.00 price target on the stock. Zacks Investment Research downgraded Connect Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, April 6th. Finally, Piper Sandler cut Connect Biopharma from an “overweight” rating to a “neutral” rating in a report on Thursday, May 5th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $19.44.

Shares of Connect Biopharma stock opened at $0.84 on Wednesday. The stock’s fifty day moving average is $1.76 and its 200-day moving average is $3.46. Connect Biopharma has a 12-month low of $0.56 and a 12-month high of $29.27.

Several large investors have recently modified their holdings of CNTB. Vident Investment Advisory LLC acquired a new position in Connect Biopharma during the first quarter valued at approximately $55,000. Renaissance Technologies LLC purchased a new stake in Connect Biopharma in the 4th quarter valued at about $56,000. Goldman Sachs Group Inc. purchased a new stake in shares of Connect Biopharma during the 4th quarter worth approximately $61,000. Chicago Partners Investment Group LLC bought a new position in Connect Biopharma in the 4th quarter worth approximately $97,000. Finally, Ensign Peak Advisors Inc bought a new position in Connect Biopharma in the 4th quarter worth approximately $131,000. Institutional investors own 34.21% of the company’s stock.

Connect Biopharma Company Profile (Get Rating)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

Featured Articles

Earnings History and Estimates for Connect Biopharma (NASDAQ:CNTB)

Want More Great Investing Ideas?

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with's FREE daily email newsletter.